52 search results for: mechanism of disease

Under the Itchy Surface: The Insidious, Cumulative Burden <b>of</b> Type 2 Inflammation in AD
Dermatology
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
expert video

In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.

View more
Under the Itchy Surface: The Insidious, Cumulative Burden <b>of</b> Type 2 Inflammation in AD
Dermatology
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
expert video

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

View more
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin <b>disease</b> (AD, PN, CSU)?
Dermatology
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?
expert video

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.

View more
Spotlight on Type 2 Inflammation in the Upper and Lower Airways
Pulmonology
Spotlight on Type 2 Inflammation in the Upper and Lower Airways
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

View more
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study <b>of</b> Pediatric Patients With AD and Type 2 Comorbidities
Dermatology
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.

View more
World Congress <b>of</b> Dermatology (WCD) 2023 | Singapore
Congress
4
July
2023
Congress
World Congress of Dermatology (WCD) 2023 | Singapore

Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.

Can advanced systemic therapies modify patho<b>mechanism</b>s in AD?
Dermatology
Can advanced systemic therapies modify pathomechanisms in AD?
expert video

Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.

View more
ADVENT at ISDS 2023: Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch
Congress
16
November
2023
Congress
ADVENT at ISDS 2023: Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

Highlights from the ADVENT symposium at the Inflammatory Skin Disease Summit (ISDS) 2023 exploring the role of type 2 inflammation in atopic dermatitis.

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
Dermatology
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
expert video

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

View more
European Academy <b>of</b> Allergy and Clinical Immunology (EAACI) 2023 | Hamburg
Congress
9
June
2023
Congress
European Academy of Allergy and Clinical Immunology (EAACI) 2023 | Hamburg

Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.

.
Congress
1
December
2023
Congress
Global ADVENT FORUM 2023, Dermatology Section | Madrid

New expert presentations from the 2023 ADVENT FORUM, Dermatology section, where the global faculty discuss itch as the common thread in dermatological type 2 inflammation, the evolving concept of disease modification in atopic dermatitis, and the latest updates in prurigo nodularis and chronic spontaneous urticaria.

From Protective Type 2 Immunity to Aberrant Type 2 Inflammation
Type 2 Inflammation
From Protective Type 2 Immunity to Aberrant Type 2 Inflammation
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 immunity evolved to protect against parasites, venoms, and toxins, and how its dysregulation can result in aberrant type 2 inflammation underlying multiple chronic inflammatory diseases.

View more